Signaturefd, LLC Denali Therapeutics Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 564 shares of DNLI stock, worth $13,925. This represents 0.0% of its overall portfolio holdings.

Number of Shares

564

Previous 534 5.62%

Holding current value

$13,925

Previous $12,000 33.33%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	BUY	$20.96 - $31.05 $628 - $931	30 Added 5.62%	564 $16,000
Q2 2024 Jul 29, 2024	SELL	$14.96 - $23.22 $2,932 - $4,551	-196 Reduced 26.85%	534 $12,000
Q1 2024 May 03, 2024	SELL	$15.83 - $23.35 $3,007 - $4,436	-190 Reduced 20.65%	730 $14,000
Q4 2023 Jan 31, 2024	BUY	$16.2 - $23.18 $4,762 - $6,814	294 Added 46.96%	920 $19,000
Q3 2023 Nov 03, 2023	BUY	$20.63 - $30.17 $6,189 - $9,051	300 Added 92.02%	626 $12,000
Q2 2023 Aug 01, 2023	BUY	$23.37 - $32.96 $2,453 - $3,460	105 Added 47.51%	326 $9,000
Q1 2023 Apr 28, 2023	BUY	$21.91 - $32.67 $2,760 - $4,116	126 Added 132.63%	221 $5,000
Q4 2022 Jan 27, 2023	BUY	$26.28 - $33.92 $1,445 - $1,865	55 Added 137.5%	95 $2,000
Q3 2022 Nov 08, 2022	BUY	$25.97 - $38.53 $908 - $1,348	35 Added 700.0%	40 $1,000
Q2 2022 Aug 10, 2022	SELL	$20.88 - $35.19 $1,002 - $1,689	-48 Reduced 90.57%	5 $0
Q1 2022 May 02, 2022	BUY	$29.0 - $47.27 $1,537 - $2,505	53 New	53 $2,000
Q2 2021 Jul 26, 2021	SELL	$50.3 - $78.44 $3,370 - $5,255	-67 Closed	0 $0
Q1 2021 Apr 30, 2021	BUY	$53.8 - $81.53 $3,066 - $4,647	57 Added 570.0%	67 $4,000
Q4 2020 Feb 11, 2021	BUY	$36.89 - $93.56 $368 - $935	10 New	10 $1,000

Others Institutions Holding DNLI

# of Institutions

228

Shares Held

120M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.31B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account